Table 3 Determinants of the use of antithrombotic therapies for stroke prevention in AF patients (see also Supplemental Table 2–5).

From: Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey

Antithrombotic therapy

Univariate analysis (significant variables only)

Multivariate analysis

Antithrombotic therapy

Multivariate analysis

OAC only

OR

95%CI

P

OR

95%CI

P

DAPT

OR

95%CI

P

HASBLED (cont. variable)

1.08

1.01–1.16

0.042

   

PCI

4.47

2.69–7.43

<0.001

Age≥80 years

0.62

0.50–0.78

<0.001

0.54

0.37–0.79

0.002

Coronary artery disease (any)

9.67

5.81–16.10

<0.001

Hypertension

1.67

1.36–2.05

<0.001

1.85

1.30–2.63

0.001

COPD

1.95

1.14–3.33

0.015

Prior MI

0.47

0.36–0.61

<0.001

0.58

0.37–0.91

0.018

Known history of AF

0.45

0.28–0.72

0.001

Prior PCI

0.32

0.22–0.47

<0.001

   

Paroxysmal AF

2.31

1.45–3.69

<0.001

Coronary artery disease (any)

0.49

0.41–0.60

<0.001

       

Stable coronary artery disease

0.55

0.46–0.67

<0.001

       

Mitral valve disease

1.40

1.15–1.70

0.001

1.56

1.07–2.28

0.021

    

Dilated cardiomyopathy

2.06

1.40–3.04

<0.001

1.72

1.10–2.68

0.018

Dual or triple therapy

OR

95%CI

P

CKD on dialysis

0.16

0.04–0.60

0.007

   

Age≥80 years

0.58

0.39–0.88

0.009

COPD

0.73

0.57–0.94

0.016

   

PCI

3.69

2.46–5.46

<0.001

Thyroid disease

1.54

1.13–2.11

0.007

   

Coronary artery disease (any)

2.78

1.94–4.00

<0.001

Known history of AF

2.53

2.07–3.08

<0.001

1.51

1.04–2.20

0.032

Hospital–based centre

2.99

1.51–5.91

0.002

Paroxysmal AF

0.38

0.32–0.46

<0.001

0.44

0.32–0.62

<0.001

HASBLED (cont. variable)

1.24

1.11–1.38

<0.001

Body mass index

1.06

1.04–1.08

<0.001

1.04

1.01–1.08

0.031

    

Centre in the capital city

2.02

1.68–2.43

<0.001

2.14

1.50–3.05

<0.001

    

University centre

2.09

1.62–2.69

<0.001

       

Cardiologist

1.55

1.26–1.92

<0.001

       

Antiplatelet drug only

OR

95%CI

P

OR

95%CI

P

OAC (alone or in combination)

OR

95%CI

P

CHA2DS2-VASc (cont. variable)

1.08

1.01–1.16

0.021

   

HASBLED≥3

1.28

1.02–1.61

0.036

Age ≥80 years

1.88

1.42–2.49

<0.001

1.99

1.46–2.73

<0.001

Hypertension

1.76

1.40–2.22

<0.001

Coronary artery disease (any)

1.63

1.26–2.10

<0.001

1.35

1.03–1.77

0.033

Age≥80 years

0.52

0.39–0.67

<0.001

Stable coronary artery disease

1.59

1.23–2.07

<0.001

   

Coronary artery disease (any)

0.74

0.60–0.92

0.007

Aortic valve disease

2.52

1.64–3.86

<0.001

1.52

1.06–2.17

0.022

Mitral valve disease

1.29

1.03–1.62

0.030

Other cardiac disease

0.50

0.28–0.90

0.021

   

Dilated cardiomyopathy

1.76

1.15–2.67

0.009

Prior TIA

1.78

1.01–3.13

0.047

   

Thyroid disease

1.57

1.10–2.25

0.013

COPD

1.56

1.13–2.16

0.007

1.55

1.09–2.19

0.014

Known history of AF

1.50

1.16–1.93

0.002

Body mass index

0.96

0.93–0.99

0.003

0.97

0.94–0.99

0.033

Paroxysmal AF

0.32

0.24–0.42

<0.001

Known history of AF

0.57

0.43–0.74

<0.001

0.68

0.51–0.91

0.010

Body mass index

1.06

1.03–1.08

<0.001

Paroxysmal AF

1.91

1.50–2.48

<0.001

2.42

1.84–3.20

<0.001

Centre in the capital city

1.98

1.58–2.49

<0.001

Centre in the capital city

0.45

0.34–0.59

<0.001

0.40

0.30–0.54

<0.001

Treatment by a cardiologist

1.37

1.06–1.78

0.016

Treatment by a cardiologist

0.68

0.51–0.90

0.007

0.67

0.50–0.91

0.010

    
  1. OAC: oral anticoagulant; OR: Odds Ratio; CI: Confidence Interval; DAPT: dual antiplatelet drug therapy; AF: atrial fibrillation; MI: Myocardial infarction; PCI: percutaneous coronary intervention; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; TIA: transient ischemic attack.
Back to article page